9104 RESULTS
COMMENT I am a retired neurologist with Alzheimer’s disease. I am an APOE-4 homozygote, and participated in the ENGAGE trial. I was in the placebo arm of the 18-month double-blind portion, and then entered the open-label continuation. I had no significant side ...
COMMENT We are disappointed that the Advisory Committee recommendation disregarded clinical evidence and patient experience. We will respond promptly to the statistical questions raised by the Committee and bring clarification that is much needed for the ...
COMMENT A recent study in Nature finds that microglia sense ATP and then inhibit neuronal activity (Badimon et al., 2020). Thus, if there is less ATP production by astrocytes then maybe there is also less inhibition by microglia? Additionally, another new Nature ...
COMMENT Suppressing or slowing the progression of AD is thought to be a pathological condition shown in the reference paper. It has been shown that even if Aβ is deposited, disease onset can be suppressed or delayed by suppressing the spread of tau pathology. ...
COMMENT This is a very intriguing and detailed analysis regarding the functional consequences of 3R tau in astrocytes. It is an important reminder that much remains to be learned about the functional consequences of pathological tau in astrocytes. Several older ...
COMMENT It was stimulating to read these assorted comments on the recent turndown of aducanumab by the FDA advisory committee. Another defeat, perhaps temporary, for the amyloid hypothesis of Alzheimer's. Most comments were devoted to salvaging it. But no ...
COMMENT I hope that this experiment can be repeated in a human CD33 transgenic mouse that has been crossed into an Alzheimer's model. There is strong unpublished evidence to suggest that CD33 is involved in the regulation of the phagocytosis or trogocytosis ...
COMMENT This elegant study by Richetin and colleagues has several interesting and important findings. In human participants with Alzheimer's disease, 3R tau accumulation was observed in astrocytes in the hippocampus, specifically the hilus of the dentate ...
COMMENT This is a very interesting study that highlights the susceptibility of astrocytes to preferentially acquire pathological features in the form of confirmation-specific isoforms of tau in hippocampal regions burdened by Alzheimer pathology. Seeking to ...
COMMENT In this important study, Richetin et al. demonstrate that astrocytes in the hilus of the hippocampus dentate gyrus accumulate misfolded 3R-tau in Alzheimer’s disease (AD). Using an elegant lentiviral gene transfer approach in vivo (wild-type mice) and in ...
COMMENT Like Séverine Boillée’s landmark observations in 2003, this elegant study once more highlights the therapeutic potential of myeloid cells in motor neuron disease. It would be fascinating to find out how and which bone marrow- and yolk-sac-derived ...
COMMENT The negative vote on Biogen’s aducanumab filing by the FDA Advisory Committee constitutes a clear setback for future availability of this antibody to oligomeric Aβ for Alzheimer patients. The basis for this vote, and its implications, needs to be ...
COMMENT We will see the results of further studies based on the amyloid hypothesis as studies continue to be pursued globally. We and others have suggested important caveats to interpreting clinical trial results. Broader thinking is now occurring across the ...
COMMENT It’s not over yet! We all wanted to believe that aducanumab would spell the beginning of the end of AD-related dementia. But the evidence that this promising anti-amyloid treatment might buck the unfortunate historical trend haunting anti-amyloid ...
COMMENT Time to think outside the box Common sense has prevailed. The failing approach to AD therapy we have implemented so far reflects the faulty attitude we have toward neurodegeneration (Hurtley and Alderton, 202 0). A growing body of evidence supports the ...
